上海毕得医药科技股份有限公司关于公司董事辞职暨选举职工董事的公告

Core Viewpoint - The announcement details the resignation of two board members, Zhao Yun and Zhang Ruihao, and the election of two employee representative directors, Shang Zhuoting and Xu Lijiao, at Shanghai Bid Pharmaceutical Technology Co., Ltd. [2][4] Group 1: Board Resignation - Zhao Yun resigned from her positions as a director, audit committee member, and compensation and assessment committee member due to internal work adjustments, while Zhang Ruihao resigned as a director and strategic committee member [2][4] - Zhao Yun will continue to fulfill her duties until a new audit committee member is elected, as her resignation would otherwise leave the committee below the legal minimum [4] - Zhao Yun indirectly holds approximately 173,499 shares, accounting for about 0.1909% of the company's total equity, while Zhang Ruihao does not hold any shares [4] Group 2: Election of Employee Representative Directors - The company held a staff representative meeting on August 8, 2025, where Shang Zhuoting and Xu Lijiao were elected as employee representative directors [5] - The election results were publicly announced, and no objections were raised during the public notice period, making the results effective automatically [5] - The number of employee representative directors does not exceed half of the total board members, complying with relevant laws and regulations [5] Group 3: Background of Newly Elected Directors - Shang Zhuoting has a diverse background in sales and management, previously holding positions at various companies, including serving as the sales director for the China region at Shanghai Bluewood Chemical Co., Ltd. [8] - Xu Lijiao has experience in sales and management roles, including serving as the general manager of Shanghai Zhizhong Pharmaceutical Technology Co., Ltd. prior to her current position [10] - Both newly elected directors do not have any direct or indirect shareholdings that would conflict with their roles and meet the qualifications required by law [9][11]